Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 29;13:8105–8118. doi: 10.2147/IJN.S184262

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Braham et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Free and liposomal chemotherapy tested in the 3D myeloma–BM model.

Notes: (A) Confocal overview pictures showing 3D cocultures 48 hours after treatment. MSCs, EPCs, and myeloma cells were visualized staining f-actin (phalloidin, red). The border of each plug is indicated by a white dashed circle. The insertion site of each culture is indicated by a dotted white circle. The scale bars represent 1,000 µm. Cultures were treated with doxorubicin (six left images) or bortezomib (six right images) both with free drug, untargeted liposomes, and VLA-4 targeted liposomes (both ~75 nm). Controls were taken along with no treatments or sham treatments (PBS or empty liposomes). (B) Quantification of viable myeloma cells, 48 hours after doxorubicin treatment and (C) bortezomib treatment. (D) Quantification of viable supporting cells, 48 hours after doxorubicin treatment and (E) bortezomib treatment. Data are presented as mean ± SD (n=3). **P<0.01, ***P<0.001.

Abbreviations: EPCs, endothelial progenitor cells; MSCs, mesenchymal stromal cells; VLA-4, very late antigen-4.

Free and liposomal chemotherapy tested in the 3D myeloma–BM model.

Notes: (A) Confocal overview pictures showing 3D cocultures 48 hours after treatment. MSCs, EPCs, and myeloma cells were visualized staining f-actin (phalloidin, red). The border of each plug is indicated by a white dashed circle. The insertion site of each culture is indicated by a dotted white circle. The scale bars represent 1,000 µm. Cultures were treated with doxorubicin (six left images) or bortezomib (six right images) both with free drug, untargeted liposomes, and VLA-4 targeted liposomes (both ~75 nm). Controls were taken along with no treatments or sham treatments (PBS or empty liposomes). (B) Quantification of viable myeloma cells, 48 hours after doxorubicin treatment and (C) bortezomib treatment. (D) Quantification of viable supporting cells, 48 hours after doxorubicin treatment and (E) bortezomib treatment. Data are presented as mean ± SD (n=3). **P<0.01, ***P<0.001.

Abbreviations: EPCs, endothelial progenitor cells; MSCs, mesenchymal stromal cells; VLA-4, very late antigen-4.